PATENT COOPERATION TREATY

PCT

HEC.D	20	LER	2005	
WIPO	,		PCT	

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

(Chapter II of the Patent Cooperation Treaty)

(PCT Article 36 and Rule 70)

				,	
Applicant's or agent's 100807-1 WO	ile reference	FOR FURTHER	ACTION	See Form PCT/IPEA/416	
International application No. International filing da PCT/GB2004/000550 11.02.2004		e (day/month/year)	Priority date (day/month/year) 13.02.2003		
International Patent Cl	assification (IPC) or n	ational classification and	IPC		
A61K31/4745, A6 ⁻	IK31 <i>1</i> 513, A61K3 [.]	1/517		•	
•					
Applicant					
ASTRAZENECA AB et al					
This report is t Authority unde	he international pre r Article 35 and trar	liminary examination in the second se	eport, established by the	nis International Preliminary Examining 36.	
2. This REPORT	consists of a total of	of 6 sheets, including	this cover sheet.		
		y ANNEXES, compris			
a. □ sent to	the applicant and to	the International Bur	eau) a total of sheets,	as follows:	
,					
b. 🛭 (sent to	Cupplemental box.				
0040011	oo nomina amakii tab	ies relateu merein in .	computer readable form 02 of the Administrative	o obligio de la diseate al facilita O	
	,		or of the Administrative	msu ucuons).	
7					
4. This report con	tains indications rel	ating to the following i	tems:		
Box No. I	Basis of the opin	ion			
☐ Box No. II	Priority				
☑ Box No. III	Non-establishme	ent of opinion with rega	ard to novelty, inventive	sten and industrial applicability	
☐ Box No. IV	Lack of unity of i	nvention	ard to novelty, inventive step and industrial applicability		
⊠ Box No. V	Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement				
☐ Box No. VI	Certain documer	nts cited	-		
Box No. VII		n the international app			
Box No. VIII Certain observations on the international application					
Date of submission of the demand Date of completion of this report			ds report		
				is report	
24.08.2004			01.03.2005		
Name and mailing address of the international preliminary examining authority:			Authorized Officer		
European Patent Office - P.B. 5818 Patentiaan 2			ggedaches Peterson, E		
NL-2280 HV Rijswijk - Pays Bas Tel. +31 70 340 - 2040 Tx: 31 651 epo nl			Leherte, C		
Fax: +31	70 340 - 3016	- · opo iii	Telephone No. +31 70 3	140-2748	
			l		

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No. PCT/GB2004/000550

_		ox No. i	Basis of the r				
-				·			
1	. Wi file	ith regarded, unles	d to the langua g s otherwise indic	e, this report is bas ated under this ite	sed on the internati m.	onal application in th	e language in which it wa
		WINOII	is the language	o a translation lum	iisnea for the purpo	ge into the following la	anguage ,
		☐ inte	rnational search lication of the in	(under Rules 12.3 ternational applicat	and 23.1(b)) ion (under Rule 12 under Rules 55.2 a	4)	
2	2. With regard to the elements* of the international application, this report is based on (replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report):						
	Des	scription,	, Pages				
	1-3	9		as originally file	ed		
	Cla	ims, Nun	nbers				
	1-14	4		as originally file	ed		
		a seque	ence listing and/	or any related table	(s) - see Suppleme	ental Box Relating to	Sequence Listing
3.			endments have description, page	resulted in the can	cellation of:		
		☐ the d	claims, Nos.	75		•	,
		☐ the o	drawings, sheets	/figs			
		□ any	sequence listing table(s) related	(specify): o sequence listing	(specify):		
4.		plement	al Box (Rule 70.	2(c)).	ne of) the amendm sidered to go beyor	ents annexed to this nd the disclosure as f	report and listed below iled, as indicated in the
		⊔ the o	lescription, page claims, Nos.	s			
		☐ the c	lrawings, sheets	figs		•	
		☐ the s	equence listing	(specify):			
				sequence listing			
	*	If ite	m 4 applies,	some or all c	f these sheets	may be marked	"superseded "

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No. PCT/GB2004/000550

	ox No. III Non-establishment opplicability	of o	pinion with regard to novelty, inventive step and industrial	
1. T	The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non- obvious), or to be industrially applicable have not been examined in respect of:			
	the entire international application,			
×	claims Nos. 14 with respect to industrial applicability			
	because:			
×	the said international application, or the said claims Nos. 14 with respect to industrial applicability relate to the following subject matter which does not require an international preliminary examination (specify):			
	see separate sheet			
	the description, claims or drawings (indicate particular elements below) or said claims Nos. are so unclear that no meaningful opinion could be formed (specify):			
	the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed.			
	no international search report has been established for the said claims Nos.			
	the written form		has not been furnished	
			does not comply with the standard	
	the computer readable form		has not been furnished	
			does not comply with the standard	
	the tables related to the nucleotic not comply with the technical req	de a Juire	and/or amino acid sequence listing, if in computer readable form only, do ements provided for in Annex C-bis of the Administrative Instructions.	
	See separate sheet for further de	etails	s	

Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)

Yes: Claims

No: Claims

1-14

Inventive step (IS)

Yes: Claims

No: Claims

1-14

Industrial applicability (IA)

Yes: Claims

1-13

No: Claims

14 (see separate sheet)

2. Citations and explanations (Rule 70.7):

see separate sheet

PCT/GB2004/000550

Re Item III

Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

Claim 14 relates to subject-matter considered by this Authority to be covered by the provisions of Rule 67.1(iv) PCT. Consequently, no opinion will be formulated with respect to the industrial applicability of the subject-matter of this claim (Article 34(4)(a)(i) PCT).

Re Item V

Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1) The following document is referred to in this communication:

D1: WO 01/32651 A

2) NOVELTY

The subject-matter of claims 1-14 is not new in the sense of Article 33 (2) PCT. Document D1 already discloses the combined use of ZD6474 and 5-Fu or CPT-11 in antiangiogenic and/or vascular permeability reducing treatment.

3) INVENTIVE STEP

Should the Applicant nevertheless overcome the objections of lack of novelty raised above, then his attention is drawn to the fact that the present claims would not meet the requirements of Article 33(3) PCT, because the subject matter of the claims would not involve an inventive step.

The use of a combination of two or more active ingredients with known identical therapeutic use can only be considered as inventive when a surprising effect, an unexpected high synergistic effect or reduced side effects for example, can be assigned in relation to the claimed therapeutic use. In this respect, the present application lacks supportive evidence as the results of the comparative tests on pages 36 and 39 do not

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY (SEPARATE SHEET)

International application No.

PCT/GB2004/000550

show more then additive effects..

- 4) INDUSTRIAL APPLICABILITY
- 4.1) There are not doubts about the industrial applicability of claims 1-13.
- 4.2) For the assessment of the present claims 14 on the question whether they are industrially applicable, no unified criteria exist in the PCT Contracting States. The patentability can also be dependent upon the formulation of the claims. The EPO, for example, does not recognize as industrially applicable the subject-matter of claims to the use of a compound in medical treatment, but may allow, however, claims to a known compound for first use in medical treatment and the use of such a compound for the manufacture of a medicament for a new medical treatment.